SVFCX vs. DOCU, NICE, MNDY, ESTC, PCOR, TWLO, CYBR, GWRE, CFLT, and PAYC
Should you be buying Smead Value C stock or one of its competitors? The main competitors of Smead Value C include DocuSign (DOCU), NICE (NICE), monday.com (MNDY), Elastic (ESTC), Procore Technologies (PCOR), Twilio (TWLO), CyberArk Software (CYBR), Guidewire Software (GWRE), Confluent (CFLT), and Paycom Software (PAYC).
Smead Value C (NASDAQ:SVFCX) and DocuSign (NASDAQ:DOCU) are both computer and technology companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, community ranking, analyst recommendations, dividends, risk, valuation, earnings and institutional ownership.
In the previous week, DocuSign had 19 more articles in the media than Smead Value C. MarketBeat recorded 19 mentions for DocuSign and 0 mentions for Smead Value C. DocuSign's average media sentiment score of 0.69 beat Smead Value C's score of 0.00 indicating that DocuSign is being referred to more favorably in the news media.
DocuSign has a net margin of 2.68% compared to Smead Value C's net margin of 0.00%. DocuSign's return on equity of 13.91% beat Smead Value C's return on equity.
DocuSign has a consensus target price of $60.25, indicating a potential upside of 10.07%. Given DocuSign's higher possible upside, analysts clearly believe DocuSign is more favorable than Smead Value C.
DocuSign received 410 more outperform votes than Smead Value C when rated by MarketBeat users. However, 100.00% of users gave Smead Value C an outperform vote while only 59.71% of users gave DocuSign an outperform vote.
DocuSign has higher revenue and earnings than Smead Value C.
Smead Value C has a beta of 0.11, indicating that its stock price is 89% less volatile than the S&P 500. Comparatively, DocuSign has a beta of 0.88, indicating that its stock price is 12% less volatile than the S&P 500.
60.2% of Smead Value C shares are owned by institutional investors. Comparatively, 77.6% of DocuSign shares are owned by institutional investors. 10.3% of Smead Value C shares are owned by company insiders. Comparatively, 1.7% of DocuSign shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Summary
DocuSign beats Smead Value C on 12 of the 14 factors compared between the two stocks.
Get Smead Value C News Delivered to You Automatically
Sign up to receive the latest news and ratings for SVFCX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SVFCX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
SVFCX vs. The Competition
Smead Value C Competitors List
Related Companies and Tools
